1. Published Name of the Standard for which request is being made (if previously published)

Specialty Medication Enrollment

2. Standards Material/Document

STU

3. Date of Request

Mar 06, 2023

4. Use Period

Two years

5. Reason for extension, timeline, and actions

6. Original Publication Date

7. End date of the current STU period

Apr 26, 2023

8. Length of the requested extension

9. Review Process

10. HL7 Work Group making this request and date

Pharmacy Work Group

10a. Requesting WG Date

Mar 06, 2023

11. URL of approval minutes

https://confluence.hl7.org/pages/viewpage.action?pageId=161054823#id-20230306Agenda/MeetingNotes-SpecialtyMedicationEnrolmentIG

12. HL7 Product Management Group

FHIR Management Group

12a. Management Group Date of Approval

Mar 29, 2023

13. URL of approval minutes

https://confluence.hl7.org/pages/viewpage.action?pageId=161061400

14. Is the artifact ready for final publication?

Yes

15. If not ready, please describe remaining steps.

16. Tool name used to produce the machine processable artifacts in the IG

FHIR IG Publisher

17. The name of the “IG artifact” within the context of the above mentioned tool.

Specialty Medication Enrollment (specialty-rx.xml)

18. Balloted Name of the standard for which request is being made

Specialty Medication Enrollment

19. Requested name for published standard. See Naming Examples

Specialty Medication Enrollment

19a. Specification Feedback Name (For Search in Jira)

20. If CMET, list IDs balloted

21. Project Insight Number

1573

22. Document Realm

U.S. Realm Specific

23. Ballot cycle in which the document was successfully balloted

2022-SEP

25. Affirmative

77

26. Negative

3

27. Abstentions

33

28. Not Returned

33

29. Total in ballot pool

146

30. Date on which final document/standards material was supplied to HQ

31. URL of publication material/ SVN repository

https://github.com/HL7/fhir-specialty-rx

32. Publishing Facilitator

Frank McKinney

33. Special Publication Instructions

34. URL of ballot reconciliation document

https://jira.hl7.org/secure/attachment/23621/reconciliation.xls

35. Has the Work Group posted its consideration of all comments received in its reconciliation document on the ballot desktop?

Yes

36. Substantive Changes Since Last Ballot?

Yes

37. Product Brief Reviewed By

Pharmacy Work Group

38. Date Product Brief Reviewed

Mar 06, 2023

39. Has the Product Brief changed?

40. Family

FHIR

41. Section

Implementation Guides

42. Topic

Medical Records Patient Care Pharmacy

43. Please Describe the Topic

44. Product Type

Implementation Guide

45. Parent standard

FHIR

46. Parent Standard Status

Active

47. Update/replace standard

Replace published STU1 of this Implementation Guide

48. Common name/search keyword

Specialty Medication Enrollment

49. Description

This FHIR implementation Guide describes the exchange of patient demographic, clinical, consent and coverage data to support fulfillment of specialty medication prescriptions by pharmacies, and enrollment of patients into related support programs offered by parties such as Hub vendors and pharmaceutical manufacturers.

50. Stakeholders

Other (specify in text box below)

51. Vendors

EHR, PHR, Health Care IT, Other (please specify)

52. Providers

Healthcare Institutions (hospitals, long term care, home care, mental health) Other (specify in text box below)

53. Benefits

Enables pharmacies and related parties to obtain the demographic, clinical, coverage and coverage information needed to dispense specialty medications in the US and enroll patients in related support programs.

54. Implementations/Case Studies

Pharmacy systems / specialty HUB systems / EHRs. The supported use cases enable (a) the prescriber's EHR to proactively exchange patient information with the pharmacy or HUB, (b) the pharmacy or HUB to systematically query patient information, (c) the pharmacy or HUB to obtain information that requires human interaction by the prescriber or their staff, and (d) the pharmacy or HUB to obtain consent information needed during dispensing of the medication.

55. Development Background

This Implementation Guide was developed in cooperation with the National Council for Prescription Drug Programs (NCPDP).







1 Comment